Suzuki Takashi, Miki Yasuhiro, Moriya Takuya, Shimada Norihiro, Ishida Takanori, Hirakawa Hisashi, Ohuchi Noriaki, Sasano Hironobu
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Cancer Res. 2004 Jul 1;64(13):4670-6. doi: 10.1158/0008-5472.CAN-04-0250.
Estrogen-related receptor alpha (ERRalpha) was identified as a gene related to estrogen receptor alpha (ERalpha) and belongs to a class of nuclear orphan receptors. ERRalpha binds to estrogen responsive element(s) (ERE) and is considered to be involved in modulation of estrogenic actions. However, biological significance of ERRalpha remains largely unknown. Therefore, we examined the expression of ERRalpha in human breast carcinoma tissues using immunohistochemistry (n = 102) and real-time reverse transcription-PCR (n = 30). ERRalpha immunoreactivity was detected in the nuclei of carcinoma cells in 55% of breast cancers examined, and relative immunoreactivity of ERRalpha was significantly (P = 0.0041) associated with the mRNA level. Significant associations were detected between ERalpha and ERE-containing estrogen-responsive genes, such as pS2 (P < 0.0001) and EBAG9/RCAS1 (P = 0.0214), in breast carcinoma tissues. However, no significant association was detected between ERalpha and pS2 (P = 0.1415) in the ERRalpha-positive cases (n = 56) or between ERalpha and EBAG9/RCAS1 (P = 0.8271) in the ERRalpha-negative group (n = 46). ERRalpha immunoreactivity was significantly associated with an increased risk of recurrence and adverse clinical outcome by both uni- (P = 0.0097 and P = 0.0053, respectively) and multi- (P = 0.0215 and P = 0.0118, respectively) variate analyses. A similar tendency was also detected in the group of breast cancer patients who received tamoxifen therapy after surgery. Results from our study suggest that ERRalpha possibly modulates the expression of ERE-containing estrogen-responsive genes, and ERRalpha immunoreactivity is a potent prognostic factor in human breast carcinoma.
雌激素相关受体α(ERRα)被鉴定为一种与雌激素受体α(ERα)相关的基因,属于核孤儿受体类别。ERRα与雌激素反应元件(ERE)结合,被认为参与雌激素作用的调节。然而,ERRα的生物学意义在很大程度上仍不清楚。因此,我们使用免疫组织化学(n = 102)和实时逆转录PCR(n = 30)检测了ERRα在人乳腺癌组织中的表达。在55%的检测乳腺癌中,癌细胞核中检测到ERRα免疫反应性,ERRα的相对免疫反应性与mRNA水平显著相关(P = 0.0041)。在乳腺癌组织中,检测到ERα与含ERE的雌激素反应基因之间存在显著关联,如pS2(P < 0.0001)和EBAG9/RCAS1(P = 0.0214)。然而,在ERRα阳性病例(n = 56)中,ERα与pS2之间未检测到显著关联(P = 0.1415),在ERRα阴性组(n = 46)中,ERα与EBAG9/RCAS1之间也未检测到显著关联(P = 0.8271)。通过单变量(分别为P = 0.0097和P = 0.0053)和多变量分析(分别为P = 0.0215和P = 0.0118),ERRα免疫反应性与复发风险增加和不良临床结局显著相关。在术后接受他莫昔芬治疗的乳腺癌患者组中也检测到了类似趋势。我们的研究结果表明,ERRα可能调节含ERE的雌激素反应基因的表达,并且ERRα免疫反应性是人类乳腺癌的一个有力预后因素。